Full Press Release Details
Provides Corporate Update on Financing and Investor Relations
Toronto, Ontario–(March 5, 2024) – Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (“Medicus” or the “Company”) is pleased to announce the appointment of Erica Monaco as Chief Operating Officer.
Ms. Monaco is an accomplished C-suite professional with a successful track record as a leader in the pharmaceutical industry. She has spent the last decade in the dermatology sector with an extensive track record of building start-up operations, accelerating change, and driving process improvement. Mostly recently, Erica was the CEO of Biofrontera Inc. (NASDAQ: BFRI). In her role as the CEO of Biofrontera, where she joined as “employee #2”, Erica grew a pre-commercial organization from FDA approval through market introduction and commercial launch, posting a revenue growth at a CAGR over 80% and completing an accretive M&A transaction. Under her watch Biofrontera completed a successful Initial Public Offering (IPO) listing on NASDAQ in 2021 and follow on equity investment rounds in excess of $60M.
Ms. Monaco holds a Master of Accounting degree from the Isenberg School of Management at the University of Massachusetts, Amherst and holds an active CPA license.
“We are delighted to welcome Erica to our leadership team” stated Dr. Raza Bokhari, Executive Chairman and CEO. “Erica brings immense business leadership experience in non-melanoma skin diseases (NMSD), strengthening our efforts to deliver a first in class, novel, non-invasive alternative to treat Basal Cell Carcinoma (BCC) of the skin, using dissolvable microneedle arrays loaded with the chemotherapeutic agent Doxorubicin (D-MNA).”
The Company also announced that it is has engaged a full-service Investment Bank in the United States to advise on potential financings and US listing opportunities. Information on any future financings will be released once available in accordance with applicable securities laws.
The Company also announced that it has engaged Renmark Financial Communications Inc. (Renmark) to increase market and brand awareness of the company and to broaden its reach within the investment community.
Under the agreement, Renmark will receive compensation of $8,000 per month, payable monthly in advance. The agreement is for an initial term of seven months commencing on March 1 st 2024 and ending on September 30 th 2024, and will renew for additional one-month terms unless terminated.
Renmark Financial Communications does not have any interest, directly or indirectly, in Medicus Pharma Ltd. or its securities, or any right or intent to acquire such an interest.
For further information contact:
Carolyn Bonner, President (610) 636-0184 cbonner@medicuspharma.com
LHA Investor Relations Tirth T. Patel 212-201-6614 tpatel@lhai.com
About Medicus Pharma Ltd:
Medicus Pharma Ltd. (TSXV: MDCX) is a holding company focused on accelerating clinical development programs of novel life sciences and bio-technology companies
SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells.
Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes statements regarding potential financing and US listing opportunities, future- oriented financial information with respect to prospective financial performance, financial position or cash flows that is presented as a forecast or a projection. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “might”, “will”, “will likely result”, “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target” or the negative and/or inverse of such terms or other similar expressions.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s public filings on SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Readers are cautioned that the foregoing list is not exhaustive and readers are encouraged to review the Prospectus accessible on the Company’s profile on SEDAR+ at www.sedarplus.ca . Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/200367